Ivabradine is a new class of selective heart rate lowering agent. It acts by selective and specific inhibition of cardiac pacemaker lf channel, in the sinus node. Ivabradine decreases the slope of the diastolic depolarization potential, prolonging the time to action potential firing. This action results in a reduction of heart rate at rest and during exercise, with little or no effects on mean arterial blood pressure or left ventricular pressure.

Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who has contraindications or intolerance with beta- blockers.

Usual recommended starting dose is 5 mg twice daily which may be increased after 3-4 weeks of treatment to 7.5 mg twice daily, depending on therapeutic response. It may be adjusted to 2.5 mg twice daily as necessary. Usual dose is one tablet in the morning and one tablet in the evening during meal.

Visual symptoms (Luminous Phenomena), blurred vision, bradycardia, 1st degree AV-block, ventricular extra systole, dizziness etc.

Mild to moderate hypotension
Atrial fibrillation
Prolong QT syndrome
Moderate hepatic insufficiency
Severe renal insufficiency

History of hypersensitivity to Ivabradine
Resting Heart rate below 60 before treatment
Cardiogenic shock
Acute MI
Severe hypotension
Severe hepatic insufficiency
Unstable angina

Contraindicated

QT prolonging medicinal products

Ivradine 5 mg tablet: Each box contains 1 blister strips of 10 tablets
Ivradine 7.5 mg tablet: Each box contains 1 blister strips of 10 tablets